Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)

Pancreas Ductal Adenocarcinoma Clinical Trial

— CASSANDRA  

Official title:

A Randomized Phase II Trial of Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG Regimen for Stage I-III Pancreatic Ductal Adenocarcinoma (PDAC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04793932
• Other study ID #: PACT21
• Status: Recruiting
• Phase: Phase 2
• Start date: November 3, 2020
• Est. completion date: November 2023

Study information

• Verified date: March 2021
• Source: Associazione Italiana per lo Studio del Pancreas
• Contact: Michele Reni, MD
• Phone: +390226437644
• Email: reni.michele[@]hsr.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main aim of this study is to compare the efficacy of short-course versus long-course pre-operative chemotherapy with PAXG or mFOLFIRINOX in patients who receive a diagnosis of pancreatic ductal adenocarcinoma (PDAC) resectable or borderline resectable.

Description:

Pancreatic cancer is the seventh cause of death in cancer patients and more than 94% of affected patients die of cancer disease. In the majority of cases, the diagnosis is done at an advanced stage and only 10-20% of patients can be treated with a surgical resection. For this neoplasia, a radical resection may be an effective treatment. Nevertheless, results obtained with surgery alone are rather inadequate, showing a median survival of 12-14 months and 2-year survival of almost 20%: it seems evident the necessity to use complementary treatments in order to improve survival rate in this group of patients.

Pancreatic cancer can relapse locally, at the level of tumoral bed, of the regional lymph nodes, on the immediately adjacent peritoneal surface or on contiguous organs. Also, distant metastases are quite frequent, mainly to the liver, at the entire peritoneal surface and, rarely, to the extra-abdominal organs. The rapid appearance of these metastases after surgical resection strongly suggests the presence of subclinical metastatic diffusion at an early phase of the disease.

Currently, combination chemotherapy based on the mFOLFIRINOX regimen is considered the therapeutic standard in the adjuvant setting, in young and fit patients. Unfortunately, mFOLFIRINOX is burdened with strong haematological and extra-haematologic toxicity and just 2/3 of patients are able to complete the treatment. Recently, PAXG regimen [(Cisplatin (P), Abraxane (A), Capecitabine (X), Gemcitabine (G)] when compared to AG in randomized studies, showed an improvement in terms of progression-free survival (PFS) and overall survival in borderline resectable, locally advanced and metastatic patients. To date, several ongoing randomized trials are investigating the efficacy of perioperative or neoadjuvant strategies in early stage PDAC. Only few studies are available regarding neoadjuvant treatment: some are outdated, numerically inconsistent, retrospective, or not randomized. In this scenario, it aims to better investigate pre-operative therapeutic strategy.

For this purpose, two randomizations are planned.

1. FIRST RANDOMIZATION. Eligible patients will be randomized (1:1), stratifying by basal CA19.9 level (<5 ULN vs ≥ 5ULN) and centre to receive:

PAXG or mFOLFIRINOX for 4 months

2. SECOND RANDOMIZATION. Patients without progression or limiting toxicity after 4 months of the assigned chemotherapy in the study, will be randomized (1:1), stratifying by treatment assigned by the first randomization, to receive 2 further months of the same chemotherapy either BEFORE or AFTER surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 261
• Est. completion date: November 2023
• Est. primary completion date: November 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Cyto/histological diagnosis of pancreatic ductal adenocarcinoma*;

2. Clinical stage I-III disease according to TNM 8th Ed. 2017 [appendix 1];

3. Resectable or borderline resectable disease, as anatomically defined according to NCCN Guidelines Version 1.2020 - Pancreatic Adenocarcinoma [appendix 2] and biologically defined according to the International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017 (CA 19.9 > 500 IU/ml) (Isaji et al., 2018);

4. Karnofsky Performance Status > 60% [appendix 3];

5. Age 18 and = 75 years;

6. Adequate bone marrow function (GB = 3500/mm3, neutrophils =1500/mm3, platelets = 100000/mm3, Hb =10 g/dl);

7. Adequate kidney function (serum creatinine < 1.5 mg/dL);

8. Adequate liver function (ALT and AST < 3 ULN and Serum total bilirubin = 1.5 ULN);

9. No prior treatment (chemotherapy, radiotherapy and/or surgery) for pancreatic cancer;

10. Women must not be on pregnancy or lactation;

11. Patient of child-bearing potential must agree to use two medically acceptable methods of contraception (one for the patient and one for the partner) during the study and for a minimum of the following 6 months; this applies to patients of both sexes. [appendix 4];

12. Patient information and signed written informed consent.

Exclusion Criteria:

1. Other types of non-ductal tumor of the pancreas, including endocrine tumors or acinar cell adenocarcinoma, cystadenocarcinoma and other periampullary malignancies.

2. Prior or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin and of other neoplasms without evidence of disease at least from 5 years;

3. Symptomatic duodenal stenosis;

4. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment

5. Known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications

6. Clinical stage IV (including ascites or malignant pleural effusion) disease according to TNM 8th Ed. 2017 [appendix 1];

7. Locally advanced disease according to NCCN Guidelines Version 1.2020 - Pancreatic Adenocarcinoma [appendix 2];

8. Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the subject's safety or the study data integrity. These include, but are not limited to:

1. History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa)

2. History of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies

3. History of the following within 6 months prior to Cycle 1 Day 1: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or ECG abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder

9. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study

10. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study

11. Any condition that confounds the ability to interpret data from the study

12. Any familiar, sociologic or geographic conditions that can potentially interfere with the adhesion to the protocol or to the follow-up;

13. Pre-existing neuropathy, Gilbert's disease or genotype UGT1A1 * 28 / * 28.

14. mutation in DPYD

15. Inflammatory disease of the colon or rectum, or occlusion or sub-occlusion of the intestine.

16. Concurrent treatment with other experimental drugs;

17. Fructose intolerance.

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreas Ductal Adenocarcinoma

Intervention

Drug:
• PAXG
Nab-paclitaxel, cisplatin and gemcitabine drugs will be administered on day 1 and 15 every 28 days. Capecitabine tablets will be taken orally on days 1 to 28, every 28 days
• mFOLFIRINOX
Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days
• short-course chemotherapy
other two months of chemotherapy after surgery
• long-course chemotherapy
other two months of chemotherapy before surgery

Locations

Country	Name	City	State
Italy	Oncologia Medica e Prevenzione Oncologica Centro di riferimento oncologico (CRO), IRCCS	Aviano
Italy	Oncologia Medica Az. Ospedaliera Istituto Tumori "Giovanni Paolo II"	Bari
Italy	Oncologia ASST pg23	Bergamo
Italy	Oncologia Medica Azienda Universitaria Ospedaliera Policlinico Sant'Orsola-Malpighi	Bologna
Italy	Oncologia Medica dell'Az.Ospedaliera Fondazione Poliambulanza Istituto Ospedaliero	Brescia
Italy	Oncologia Medica AOU Careggi	Florence
Italy	Oncologia Ospedale Generale Provinciale	Macerata
Italy	Oncologia Medica dell'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori	Meldola
Italy	IRCCS San Raffaele	Milan
Italy	Oncologia dell'Istituto Clinico Humanitas	Milan
Italy	Oncologia Medica Falck Niguarda	Milan
Italy	Oncologia Medica Az Ospedaliera AOU Cagliari Policlinico Universitario Dullio Casula	Monserrato
Italy	Oncologia Medica AOU FEDERICO II	Naples
Italy	Oncologia Medica 1 Ospedaliera Istituto Oncologico Veneto IRCCS	Padova
Italy	Oncologia Medica Arnas Civico	Palermo
Italy	Oncologia Medica 2 Az. Ospedaliera Universitaria Pisana	Pisa
Italy	Oncologia Medica Az. Ospedaliera Fondazione Policlinico Universitario A. Gemelli IRCCS	Rome
Italy	Chirurgia Generale e Oncologica dell'AZ. Ospedaliera Ordine Mauriziano	Torino
Italy	Divisione Chirurgica Az. Ospedaliera AULSS2	Treviso
Italy	SOC di Oncologia Az. Ospedaliera Sanitaria Universitaria Friuli Centrale-P.O. "S. Maria della Misericordia"	Udine
Italy	Chirurgia generale e del Pancreas Azienda Ospedaliera Universitaria Integrata	Verona
Italy	Oncologia ULSS8 Berica	Vicenza

Sponsors (3)

Lead Sponsor	Collaborator
Associazione Italiana per lo Studio del Pancreas	Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente, High Research srl

Country where clinical trial is conducted

Italy, 

References & Publications (6)

Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Di Muzio N, Di Carlo V, Villa E. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Ann Surg Oncol. 2012 Jul;19(7):2256-63. doi: 10.1245/s10434-011-2205-2. Epub 2012 Jan 12. — View Citation

Reni M, Balzano G, Zanon S, Passoni P, Nicoletti R, Arcidiacono PG, Pepe G, Doglioni C, Fugazza C, Ceraulo D, Falconi M, Gianni L. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. Br J Cancer. 2016 Jul 26;115(3):290-6. doi: 10.1038/bjc.2016.209. Epub 2016 Jul 12. — View Citation

Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423. doi: 10.1016/S2468-1253(18)30081-5. Epub 2018 Apr 4. — View Citation

Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7. — View Citation

Reni M, Zanon S, Balzano G, Passoni P, Pircher C, Chiaravalli M, Fugazza C, Ceraulo D, Nicoletti R, Arcidiacono PG, Macchini M, Peretti U, Castoldi R, Doglioni C, Falconi M, Partelli S, Gianni L. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer. 2018 Oct;102:95-102. doi: 10.1016/j.ejca.2018.07.007. Epub 2018 Aug 24. — View Citation

Reni M, Zanon S, Peretti U, Chiaravalli M, Barone D, Pircher C, Balzano G, Macchini M, Romi S, Gritti E, Mazza E, Nicoletti R, Doglioni C, Falconi M, Gianni L. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):691-697. doi: 10.1016/S2468-1253(18)30196-1. Epub 2018 Jul 7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The efficacy of PAXG versus mFOLFIRINOX in terms of EFS	to compare in terms of event free survival (EFS) the efficacy of PAXG to that of mFOLFIRINOX. EFS is defined as the time from randomization to: RECIST 1.1 progression [At least a 20 percent increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20 percent, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression]; CA19.9 failure (defined as 2 consecutive increases of serum level =20 percent, separated by at least 4 weeks); recurrence; preoperative or intraoperative unresectability; intraoperative evidence of metastases; death for any cause; whichever occurs first. R1 resections will NOT be considered as events whereas R2 resections will be.	12 weeks
Primary	The efficacy of short-course versus long-course therapy in terms of EFS	to compare in terms of event free survival (EFS) the efficacy of 4 months pre-operative and 2 months postoperative chemotherapy to that of 6 months of pre-operative chemotherapy . EFS is defined as the time from randomization to: RECIST 1.1 progression [At least a 20 percent increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20 percent, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression]; CA19.9 failure (defined as 2 consecutive increases of serum level =20 percent, separated by at least 4 weeks); recurrence; preoperative or intraoperative unresectability; intraoperative evidence of metastases; death for any cause; whichever occurs first. R1 resections will NOT be considered as events whereas R2 resections will be.	12 weeks
Secondary	Overall survival	the time between the date of the patient's enrollment and the death of the patient for any cause or the last time the patient was seen alive	36 months
Secondary	RECIST 1.1 radiological response	Radiological response evaluation during the treatment by using RECIST 1.1 criteria	4-6 months
Secondary	Ca19.9 response rate	Biochemical response evaluation during the treatment by using this specific marker	4-6 months
Secondary	Surgery outcome	The evaluation of resectability rate.	4-6 months after chemotherapy
Secondary	Surgery outcome	The evaluation of surgical mortality and morbidity rate.	4-6 months after chemotherapy
Secondary	Surgery outcome	The evaluation of intra- and post-operative metastasis rate.	4-6 months after chemotherapy
Secondary	Surgery outcome	The evaluation of N0 and R0 resections rate.	4-6 months after chemotherapy
Secondary	Incidence of Treatment Adverse Events	The evaluation of drugs safety and tolerability by SAE report	4-6 months
Secondary	Quality of life	Impact of treatment on quality of life assessed by the latest version of the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30)	4-6 months
Secondary	Quality of life	Impact of treatment on quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life scale for pancreatic cancer (EORTC QLQ - PAN26)	4-6 months